Epigenomics AG To Enter Collaboration With AstraZeneca (AZN)
10/19/2005 5:09:42 PM
Project to use paraffin samples for the identification of biomarkers Epigenomics announced today the signing of a collaboration with AstraZeneca. In the project, Epigenomics will identify DNA methylation markers from clinical tumor samples embedded in paraffin for use in AstraZeneca’s cancer drug discovery and development program. DNA methylation is a genetic switch for gene activity that occurs in distinct patterns in cells specific for cancer and other diseases. The biomarkers discovered in this process may become part of AstraZeneca’s strategy for targeting drugs such as IRESSA, the selective epidermal growth factor receptor tyrosine kinase inhibitor.
comments powered by